Characterization of the drug resistance profiles of patients infected with CRF07-BC using phenotypic assay and ultra-deep pyrosequencing

Szu Wei Huang, Wei You Li, Wen Hung Wang, Yu Ting Lin, Chih Hung Chou, Marcelo Chen, Hsien Da Huang, Yen Hsu Chen, Po Liang Lu, Sheng Fan Wang, Shinichi Oka, Yi Ming Arthur Chen

Research output: Contribution to journalArticle

Abstract

The usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07-BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07-BC strains using different assays including UDPS. Seven CRF07-BC isolates including 4 from early epidemic (collected in 2004-2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-naïve patient's peripheral blood mononuclear cells. Viral RNA was extracted directly from patient's plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07-BC isolates were resistant to most protease inhibitors (PIs) (4.4-47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01-0.08% of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01%.

Original languageEnglish
Article numbere0170420
JournalPLoS One
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

drug resistance
Drug Resistance
Assays
assays
Pharmaceutical Preparations
proteinase inhibitors
Protease Inhibitors
Human immunodeficiency virus 1
mutation
Mutation
HIV-1
drug injection
Patient treatment
Viral RNA
mononuclear leukocytes
Drug Users
Taiwan
Disease Outbreaks
Accessories
Blood Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Characterization of the drug resistance profiles of patients infected with CRF07-BC using phenotypic assay and ultra-deep pyrosequencing. / Huang, Szu Wei; Li, Wei You; Wang, Wen Hung; Lin, Yu Ting; Chou, Chih Hung; Chen, Marcelo; Huang, Hsien Da; Chen, Yen Hsu; Lu, Po Liang; Wang, Sheng Fan; Oka, Shinichi; Chen, Yi Ming Arthur.

In: PLoS One, Vol. 12, No. 1, e0170420, 01.01.2017.

Research output: Contribution to journalArticle

Huang, Szu Wei ; Li, Wei You ; Wang, Wen Hung ; Lin, Yu Ting ; Chou, Chih Hung ; Chen, Marcelo ; Huang, Hsien Da ; Chen, Yen Hsu ; Lu, Po Liang ; Wang, Sheng Fan ; Oka, Shinichi ; Chen, Yi Ming Arthur. / Characterization of the drug resistance profiles of patients infected with CRF07-BC using phenotypic assay and ultra-deep pyrosequencing. In: PLoS One. 2017 ; Vol. 12, No. 1.
@article{fadf83f800014f6999b9935354b79bdc,
title = "Characterization of the drug resistance profiles of patients infected with CRF07-BC using phenotypic assay and ultra-deep pyrosequencing",
abstract = "The usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07-BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07-BC strains using different assays including UDPS. Seven CRF07-BC isolates including 4 from early epidemic (collected in 2004-2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-na{\"i}ve patient's peripheral blood mononuclear cells. Viral RNA was extracted directly from patient's plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07-BC isolates were resistant to most protease inhibitors (PIs) (4.4-47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01-0.08{\%} of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01{\%}.",
author = "Huang, {Szu Wei} and Li, {Wei You} and Wang, {Wen Hung} and Lin, {Yu Ting} and Chou, {Chih Hung} and Marcelo Chen and Huang, {Hsien Da} and Chen, {Yen Hsu} and Lu, {Po Liang} and Wang, {Sheng Fan} and Shinichi Oka and Chen, {Yi Ming Arthur}",
year = "2017",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0170420",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Characterization of the drug resistance profiles of patients infected with CRF07-BC using phenotypic assay and ultra-deep pyrosequencing

AU - Huang, Szu Wei

AU - Li, Wei You

AU - Wang, Wen Hung

AU - Lin, Yu Ting

AU - Chou, Chih Hung

AU - Chen, Marcelo

AU - Huang, Hsien Da

AU - Chen, Yen Hsu

AU - Lu, Po Liang

AU - Wang, Sheng Fan

AU - Oka, Shinichi

AU - Chen, Yi Ming Arthur

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07-BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07-BC strains using different assays including UDPS. Seven CRF07-BC isolates including 4 from early epidemic (collected in 2004-2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-naïve patient's peripheral blood mononuclear cells. Viral RNA was extracted directly from patient's plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07-BC isolates were resistant to most protease inhibitors (PIs) (4.4-47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01-0.08% of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01%.

AB - The usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07-BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07-BC strains using different assays including UDPS. Seven CRF07-BC isolates including 4 from early epidemic (collected in 2004-2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-naïve patient's peripheral blood mononuclear cells. Viral RNA was extracted directly from patient's plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07-BC isolates were resistant to most protease inhibitors (PIs) (4.4-47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01-0.08% of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01%.

UR - http://www.scopus.com/inward/record.url?scp=85010378988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010378988&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0170420

DO - 10.1371/journal.pone.0170420

M3 - Article

C2 - 28107423

AN - SCOPUS:85010378988

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0170420

ER -